Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Tzield
Teplizumab is a monoclonal antibody that targets CD3, a protein complex found on the surface of T cells, which are key components of the immune system. It is used to delay or prevent the onset of type 1 diabetes in at-risk individuals. Teplizumab works by modulating the immune response, specifically targeting the autoreactive T cells that attack and destroy insulin-producing beta cells in the pancreas. This immunomodulatory effect can help preserve beta cell function and delay the progression to clinical diabetes.
Teplizumab is used to delay or prevent the onset of clinical type 1 diabetes in at-risk individuals.
Outcome:
Reduced vaccine efficacy, increased risk of infection
Mechanism:
Immunosuppression
Outcome:
Increased risk of bleeding
Mechanism:
Platelet inhibition
Outcome:
Reduced teplizumab absorption
Mechanism:
Altered drug absorption
Most likely new formulation: Subcutaneous injection (2025, 70% confidence)
Based on clinical trial data, teplizumab has a high likelihood of remaining a prescription-only medication with continued monitoring for long-term safety and efficacy.
Antidiabetic Agent, Immunomodulator
Monoclonal Antibody